DUBLIN, January 23, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/n8zwpc/lyophilized) has announced the addition of the "Lyophilized Injectables" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The inherent instability of protein drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed - a requirement referred to as the cold chain'.
Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to injection. Lyophilized drugs are sold with reconstitution vial systems, or packaged in special injection devices (e.g., pens, needle-free injectors, two-part syringes) that allow reconstitution to take place in the device prior to injection What You Will Learn:
For more information visit http://www.researchandmarkets.com/research/n8zwpc/lyophilized
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Advertisement
Research and Markets (http://www.researchandmarkets.com/research/n8zwpc/lyophilized) has announced the addition of the "Lyophilized Injectables" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The inherent instability of protein drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed - a requirement referred to as the cold chain'.
Advertisement
Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to injection. Lyophilized drugs are sold with reconstitution vial systems, or packaged in special injection devices (e.g., pens, needle-free injectors, two-part syringes) that allow reconstitution to take place in the device prior to injection What You Will Learn:
- Provides detailed analysis of lyophilized drugs, as-supplied packaging and therapeutic indication
- Analyzes therapeutic demand drivers and evaluates lyophilized drugs in eleven therapeutic areas
- Analyzes lyophilization technologies and market development issues
- Provides market data and forecasts to 2020
- Profiles market participants, their product development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of technology and regulatory factors on commercialization and market access
- The Economics of lyophilized Drugs
- What's Driving the Market for Lyophilized Drugs?
- The Trend toward Self-Administration
- Shifting Demographics
- Innovation in Disposable Device Designs
- Therapeutic Demand Drivers
- Competitive Landscape
- Risk Factors
- Point-of-Care Reconstitution
- Specialty Packaging
- Drugs for SC/IM Injection
- Drugs for Infusion
- Product Specific Devices
- Proprietary Reconstitution Devices
- Single Step Devices
- Multi-Step Devices
- Human Engineering/Ergonomics
- Autoimmune Diseases
- Blood Factors
- Hormones
- Infectious Diseases
- Metabolic Conditions
- Oncology
- Reproductive Health
- Other Important Therapeutic Classes
- Market Factors
- Regulatory Issues
- Patient Compliance and Ease of Use
- Healthcare Economics
For more information visit http://www.researchandmarkets.com/research/n8zwpc/lyophilized
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
